Medexus to Present at the Sidoti & Company Virtual Microcap Conference on May 19th
- Wall Street ekes out gains to close languid week
- 'Faster than Porsche but Safer than Volvo': Tesla (TSLA) Begins Model S Plaid Deliveries, Priced Between $131,100 and $145,600
- Oil hits multi-year highs in third weekly gain on demand recovery
- Snowflake (SNOW) Falls Following Investor Day Despite Strong Guidance, Analysts Bullish But Say Investors May Have Wanted More
- Dollar looks stronger as euro and sterling dip
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
TORONTO, CHICAGO and MONTREAL, May 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Sidoti & Company Virtual Microcap Conference being held on May 19th - May 20th, 2021.
Ken d’Entremont, Chief Executive Officer, and Roland Boivin, Chief Financial Officer of Medexus, are scheduled to present on Wednesday, May 19, 2021 at 9:15 AM, Eastern Time. The presentation will be webcast live and available for replay here as well as on the Company’s website at www.medexus.com/en_US/investors/news-events. In addition to the presentation, management will also be hosting virtual one-on-one meetings throughout the day on both Wednesday, May 19th and Thursday, May 20th. Interested investors should contact the Sidoti Marketing Team at 212-453-7031 or email@example.com to schedule a meeting.
About Medexus Pharmaceuticals Inc.
Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action.
For more information, please contact:
Ken d’Entremont, Chief Executive OfficerMedexus Pharmaceuticals Inc.Tel.: 905-676-0003E-mail: firstname.lastname@example.org
Roland Boivin, Chief Financial OfficerMedexus Pharmaceuticals Inc.Tel.: 514-344-8765E-mail: email@example.com
Investor Relations (U.S.):Crescendo Communications, LLCTel: +1-212-671-1020Email: firstname.lastname@example.org
Investor Relations (Canada):Tina ByersAdelaide Capital Tel: 905-330-3275E-mail: email@example.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent
- Hot Penny Stocks to Buy Under $5? 3 You Might Not Have Heard Of
- SKT to Participate in E3 2021 to Showcase Exciting Korean Games
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Related EntitiesSidoti & Company
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!